G protein-coupled receptors

Oramed Patent in Europe to be Granted for Oral Delivery of Proteins

Retrieved on: 
Tuesday, January 28, 2020
Diabetes, Anti-diabetic drugs, Peptide hormones, Glucagon-like peptide-1, G protein-coupled receptors, Glucagon, Organ systems

Oramed Pharmaceuticalsis a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.

Key Points: 
  • Oramed Pharmaceuticalsis a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
  • Established in 2006, with offices inNew YorkandIsrael, Oramed has developed a novel Protein Oral Delivery (POD) technology that is based on more than 30 years of research by scientists atJerusalem'sHadassah Medical Center.
  • In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901 .
  • For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with theSecurities and Exchange Commission.

Orexin Receptor Type 2, Pipeline Review, H2 2019 - Inexia Ltd, Takeda Pharmaceutical & Idorsia Pharmaceutical Ltd - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 21, 2020
Health, Pharmaceutical, G protein-coupled receptors, Branches of biology, Cell biology, Hypocretin (orexin) receptor 2, Orexin receptor, Hypocretin (orexin) receptor 1, Orexin, TCS-OX2-29, Orexin antagonist

The "Orexin Receptor Type 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Orexin Receptor Type 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene.
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 8 molecules.
  • The latest report Orexin Receptor Type 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Free Fatty Acid Receptor 4, Pipeline Review, H2 2019 - AstraZeneca Plc & Micelle BioPharma Inc - ResearchAndMarkets.com

Retrieved on: 
Monday, January 20, 2020
Health, Pharmaceutical, G protein-coupled receptors, Branches of biology, GPR120, Free fatty acid receptor, GPR 120, Rhodopsin-like receptors

The "Free Fatty Acid Receptor 4 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Free Fatty Acid Receptor 4 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Free Fatty Acid Receptor 4 is a G protein-coupled receptor (GPR) encoded by FFAR4 gene.
  • It acts as a receptor for omega-3 fatty acids and mediates robust anti-inflammatory effects, particularly in macrophages and fat cells.
  • Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) pipeline Target constitutes close to 8 molecules.

Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 20, 2020
Biotechnology, Pharmaceutical, Health, Branches of biology, Drugs, Chemistry, Peptides, Peptide hormones, Appetite stimulants, G protein-coupled receptors, Growth hormone secretagogue, Protein families, Ghrelin, Growth hormone, Signaling peptide receptor

The "Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin.
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 19 molecules.
  • The latest report Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Type 2 Angiotensin II Receptor - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 16, 2020
Health, Pharmaceutical, Branches of biology, G protein-coupled receptors, Medical specialties, Angiology, Endocrinology, Hypertension, Medicine, Angiotensin II receptor, Angiotensin, EMA401, Angiotensin-converting enzyme 2

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene.

Key Points: 
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene.
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 9 molecules.
  • The latest report Type 2 Angiotensin II Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects.

Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 16, 2020
Health, Pharmaceutical, G protein-coupled receptors, Branches of biology, Cell biology, Lysophosphatidic acid receptor, LPAR1, Lysophosphatidic acid, LPAR3, LPAR2, Lipid signaling

According to the recently published report 'Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2019'; Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 7 molecules.

Key Points: 
  • According to the recently published report 'Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2019'; Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 7 molecules.
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA).
  • The report 'Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2019' outlays comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
  • It also reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics development with respective active and dormant or discontinued projects.

Sosei Heptares: Significant Progress by Orexia and Inexia With Orexin Agonist Program Triggers Next Tranche of Funding From Medicxi

Retrieved on: 
Tuesday, January 14, 2020
Branches of biology, Biology, G protein-coupled receptors, Molecular neuroscience, Neuropeptides, Protein families, Orexin, Hypocretin (orexin) receptor 2, Narcolepsy, Hypocretin (orexin) receptor 1

Mario Alberto Accardi Ph.D., CEO of Orexia and Inexia, commented:"We have assembled a unique orexin modulator drug discovery and design engine at Orexia and Inexia, based around Sosei Heptares' SBDD and GPCR technology.

Key Points: 
  • Mario Alberto Accardi Ph.D., CEO of Orexia and Inexia, commented:"We have assembled a unique orexin modulator drug discovery and design engine at Orexia and Inexia, based around Sosei Heptares' SBDD and GPCR technology.
  • This significant and exciting progress has triggered the investment of further committed funds from Medicxi that will be deployed to rapidly advance these highly promising molecules towards the clinic."
  • Dr. Malcolm Weir, Executive Vice President, Research & Early Development at Sosei Heptares, added: "We are very pleased with the progress being made in the orexin agonist program in collaboration with Orexia and Inexia and with support and funding from Medicxi.
  • Orexia and Inexia are focused on developing Orexin OX1 and OX2 positive modulators and products derived therefrom, including dual OX1/OX2 agonists, targeting neurological diseases including narcolepsy.

Sosei Heptares: Significant Progress by Orexia and Inexia With Orexin Agonist Program Triggers Next Tranche of Funding From Medicxi

Retrieved on: 
Tuesday, January 14, 2020
Branches of biology, Biology, G protein-coupled receptors, Molecular neuroscience, Neuropeptides, Protein families, Orexin, Hypocretin (orexin) receptor 2, Narcolepsy, Hypocretin (orexin) receptor 1

Mario Alberto Accardi Ph.D., CEO of Orexia and Inexia, commented:"We have assembled a unique orexin modulator drug discovery and design engine at Orexia and Inexia, based around Sosei Heptares' SBDD and GPCR technology.

Key Points: 
  • Mario Alberto Accardi Ph.D., CEO of Orexia and Inexia, commented:"We have assembled a unique orexin modulator drug discovery and design engine at Orexia and Inexia, based around Sosei Heptares' SBDD and GPCR technology.
  • This significant and exciting progress has triggered the investment of further committed funds from Medicxi that will be deployed to rapidly advance these highly promising molecules towards the clinic."
  • Dr. Malcolm Weir, Executive Vice President, Research & Early Development at Sosei Heptares, added: "We are very pleased with the progress being made in the orexin agonist program in collaboration with Orexia and Inexia and with support and funding from Medicxi.
  • Orexia and Inexia are focused on developing Orexin OX1 and OX2 positive modulators and products derived therefrom, including dual OX1/OX2 agonists, targeting neurological diseases including narcolepsy.

ESCAPE Bio Announces Excellent Safety and Tolerability in Phase 1 Study of Oral S1P5 Receptor Agonist ESB1609

Retrieved on: 
Monday, January 6, 2020
Health, Science, Pharmaceutical, Research, Clinical trials, Branches of biology, G protein-coupled receptors, Lipids, Sphingosine-1-phosphate, S1PR5, Agonist, A-971432, ESB1609, Niemann-Pick C (NPC), ESCAPE Bio

ESCAPE Bio, Inc. , a clinical stage company developing precisely targeted therapeutics for genetically defined neurodegenerative diseases, today announced that ESB1609 demonstrated durable CSF pharmacokinetics and excellent safety & tolerability in a single ascending dose Phase 1 Study.

Key Points: 
  • ESCAPE Bio, Inc. , a clinical stage company developing precisely targeted therapeutics for genetically defined neurodegenerative diseases, today announced that ESB1609 demonstrated durable CSF pharmacokinetics and excellent safety & tolerability in a single ascending dose Phase 1 Study.
  • ESB1609 is a novel, orally administered, brain-penetrant and highly-selective sphingosine 1-phosphate 5 (S1P5) receptor agonist.
  • "This initial clinical data suggests ESB1609 has durable CNS drug exposure with a single oral dose with excellent safety and tolerability.
  • ESB1609 is a novel, orally-administered, brain-penetrant and highly-selective sphingosine 1-phosphate 5 (S1P5) receptor agonist.

U.S. FDA Approves Eisai's DAYVIGO™ (lemborexant) for the Treatment of Insomnia in Adult Patients

Retrieved on: 
Monday, December 23, 2019
Psychoactive drugs, Chemical compounds, Hypnotics, Branches of biology, Organofluorides, G protein-coupled receptors, Cyclopropanes, Lemborexant, Pyrimidines, Orexin antagonist, Orexin receptor, Orexin

Patients were randomized to placebo (n=325), DAYVIGO 5 mg (n=323), or DAYVIGO 10 mg (n=323) once nightly.

Key Points: 
  • Patients were randomized to placebo (n=325), DAYVIGO 5 mg (n=323), or DAYVIGO 10 mg (n=323) once nightly.
  • Patients were randomized to placebo (n=208), DAYVIGO 5 mg (n=266) or 10 mg (n=269), or active comparator (n=263) once nightly.
  • DAYVIGO (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
  • Patients with Compromised Respiratory Function:
    The effect of DAYVIGO on respiratory function should be considered for patients with compromised respiratory function.